Although I try to stay on top of events in the life sciences, announcements do sometimes manage to slip through the cracks. Some days, in fact, I end up triaging. Because the roots of this site — not to mention …
(UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO …
(UPDATED: See below.)…
(UPDATED: See below.)
Masimo, an Irvine, Calif., maker of non-invasive patient-monitoring products, expects to raise nearly a quarter-billion dollars in an IPO. (The company’s latest filing statement is here.) That IPO take is almost $100 billion higher than Masimo …
ImaRx, a Tuscon, Ariz., biotech developing new ways to dissolve blood clots in the lungs, lowered its IPO sights and now expects to raise no more than $17.3 million in the offering. (Its latest SEC filing is here.) Late last …
Amedica, a Salt Lake City device maker focused on spine, knee and hip implants, set its IPO terms and now hopes to raise as much as $80.2 million. The company plans to sell up to 5.3 million shares at a …
(UPDATED: See below.)
Sunrise, Fla.-based Bioheart thinks enough of its stem-cell treatment for heart disease that it has just boosted its expected IPO take by $10 million, to $45 million. A close reading of its latest SEC filing, however, …
Virtual Radiologic, a Minnetonka, Minn., provider of outsourced radiology services, hopes to raise $75 million in an initial offering. The company calls itself the second-largest provider of such “teleradiology” services, in which a dispersed network of radiology specialists read and …
Quark Pharmaceuticals, the biotech chameleon I profiled here, delayed an IPO that the company expects to raise as much as $81 million, VentureWire reports (subscription required). The newswire said the Fremont, Calif., developer of RNA-interference drugs was slated to begin …
Athenahealth, a Watertown, Mass., maker of health IT systems for billing and management of electronic health records, filed to raise as much as $86.25 million in an initial offering. The company’s SEC filing is here.
Athenahealth’s systems work as Web-based …
MAP Pharmaceuticals, a Mountain View, Calif., developer of reformulated drugs for inhalation, filed to raise up to $86 million in an initial public offering. The company’s registration statement with the SEC is here.
MAP is the latest drugmaker to brave …
Bridgewater, N.J.’s Aegerion Pharmaceuticals withdrew an IPO that the company expected to raise as much as $80.5 million, citing “market conditions.” The company’s withdrawal statement is here. The company had filed to go public back in March.
Aegerion is developing …
Zars, a Salt Lake City maker of topical drugs, filed to raise up to $86.25 million in an initial offering. Its registration statement with the SEC is here, and its press release is here.
Zars specializes in topically administered drugs. …
(UPDATED: See below.)
For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific strategy, disease focus or business model, sometimes to recover from a major failure, and sometimes just to be whatever …
Reuters is reporting that Jazz Pharmaceuticals, maker of the controversial drug Xyrem, priced its six million IPO shares at $18 apiece — roughly 30% below its earlier, most optimistic hopes. Just this morning, Jazz lowered its expected range to $20 …
Cranbury, N.J.-based Amicus Therapeutics priced its IPO shares at $15, right in the middle of its expected $14 to $16 range, an offering that could raise up to $86.3 million in gross proceeds if it sells all 5.75 million shares …
(UPDATED: See below.) Jazz Pharmaceuticals, the generally unexciting specialty-pharmaceutical maker that had hoped to raise $179.4 million in an IPO, has collided with reality.
The company today lowered its expected IPO take to a maximum of $144.9 million, a …
EnteroMedics, a St. Paul, Minn., developer of obesity-treatment implants, filed to raise up to $86.25 million in an IPO. Its S-1 filing with the SEC is here.
The company is developing a neuromodulation implant called VBLOC that is designed to …
